• IAC 2020 Virtual: Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana - (07/16/20)
   
  
• IAC 2020 Virtual: Overdose Deaths Cut 10 Years Off HIV Life Expectancy: British Columbia - Mark Mascolini (07/16/20)
   
  
• IAC 2020 Virtual: Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions - (07/16/20)
   
  
• IAC 2020 Virtual: FACTORS ASSOCIATED WITH RESILIENCE AMONG OLDER PEOPLE LIVING WITH HIV - (07/16/20)
   
  
• IAC 2020 Virtual: HIV-1 DNA Testing in Viremic Patients Demonstrates a Greater Ability to Detect Drug Resistance Compared to Plasma Virus Testing - (07/16/20)
   
  
• IAC 2020 Virtual: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (07/16/20)
   
  
• IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/16/20)
   
  
• Cognitive disorders in people living with HIV - (07/16/20)
   
  
• Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV (cure) - (07/16/20)
   
  
• PrEP in YBMSM Atlanta -. high rates of discontinuation - (07/16/20)
   
  
• COVID Congress: Baseline Characteristics Associated With Clinical Improvement and Mortality in Hospitalized Patients With Severe COVID-19 Treated With Remdesivir - (07/16/20)
   
  
• COVID Congress: Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care - (07/16/20)
   
  
• GILEAD SCIENCES STATEMENT ON THE INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL OUTPATIENT TREATMENT OF COVID-19 - (07/16/20)
   
  
• European Commission Grants Conditional Marketing Authorization for Gilead's Veklury® (remdesivir) for the Treatment of COVID-19 - (07/16/20)
   
  
• IAC 2020 Virtual: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (07/16/20)
   
  
• IAC 2020 Virtual: ADEQUATE PLASMA LEVELS OF DOLUTEGRAVIR IN COMBINATION WITH RITONAVIR-BOOSTED DARUNAVIR: A PHARMACOKINETIC SUBGROUP-ANALYSIS OF THE DUALIS STUDY - (07/16/20)
   
  
More HIV Articles...
 

• UNAIDS Press release - COVID-19 could affect the availability and cost of antiretroviral medicines, but the risks can be mitigated - (06/25/20)
   
  
• UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - (06/24/20)
   
  
• Coronavirus puts drug repurposing on the fast track - (03/02/20)
   
  
• FDA Expands Coronavirus Testing in the United States - (03/02/20)
   
  
More News Updates Articles...
 

• HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - -
   
  
• EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany-
   
  
• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• IAC 2020 Virtual: Almost Half of Older HIV+ Adults Report Poor Overall Health in 25-Country Survey - (07/15/20)
   
  
• IAC 2020 Virtual: HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)
   
  
• IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - More Weight, Trunk Fat, Metabolic Syndrome With DTG+TAF/FTC in South African Trial - Mark Mascolini (07/15/20)
   
  
• IAC 2020 Virtual: Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women - Mark Mascolini (07/15/20)
   
  
• IAC 2020 Virtual: The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
   
  
• IAC 2020 Virtual: Racial Disparities, Communal Living in Boston COVID-19 Patients With HIV - Mark Mascolini (07/15/20)
   
  
• IAC 2020 Virtual: Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex With Men: A Global Systematic Review - (07/13/20)
   
  
• IAC 2020 Virtual: Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: A longitudinal analysis - (07/13/20)
   
  
• IAC 2020 Virtual: HCV Reinfection Rate 40% in Netherlands HIV+ MSM 5 Years After Clearance - Mark Mascolini (07/13/20)
   
  
• IAC 2020 Virtual: Global HCV Burden Greater in MSM, Especially HIV+ Men: Meta-Analysis - Mark Mascolini (07/13/20)
   
  
• Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH - press release - (06/29/20)
   
  
• Barriers to HCV Treatment: Prior Authorization for PWID Must Be Removed, It Delays Cure & Encourages Disease Progression & Death - (06/19/20)
   
  
More Hep C Articles...
 

• Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/11/20)
   
  
• VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial - press release - (04/20/20)
   
  
• Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection - (04/20/20)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.